Silexan is a standardized oral lavender oil preparation (80mg soft gelatin capsule, product code WS 1265) that has outperformed lorazepam in a randomized controlled trial for anxiety reduction without producing dependence, tolerance, cognitive impairment, or withdrawal effects. In a 2010 six-week RCT published in Phytomedicine, Silexan reduced Hamilton Anxiety Scale scores by 45% compared to lorazepam’s 46%, a difference that was not statistically significant. That result placed a supplement in the same clinical tier as a Schedule IV benzodiazepine for mixed anxiety disorder.
Most people who struggle with anxiety have never heard of Silexan, and that gap matters. Benzodiazepines remain the first or second-line prescription response to acute anxiety in many clinical settings despite their well-documented risks: physical dependence develops in as few as 2 to 4 weeks of daily use, cognitive impairment affects driving and workplace performance, and withdrawal can produce seizures in chronic users. Silexan operates through an entirely different neurochemical pathway, one that produces no dependence and no withdrawal.
This article covers what five clinical trials have found, the mechanism that makes Silexan work without touching GABA receptors, how it compares to SSRIs and benzodiazepines, and what to look for when selecting a product. The evidence is strong enough to warrant serious consideration for anyone who has been prescribed a benzodiazepine or is weighing whether to pursue pharmacological anxiety treatment at all.
What Silexan Is and How It Differs From Aromatherapy
Silexan is not lavender essential oil placed in a diffuser. The distinction is fundamental to understanding why the clinical evidence applies to Silexan but not to the general category of lavender aromatherapy, which lacks comparable trial data.
Silexan (WS 1265) is an oral preparation of steam-distilled lavender flower oil (Lavandula angustifolia) standardized to a defined chemical composition: 36 to 38% linalyl acetate, 25 to 38% linalool, with controlled concentrations of ocimene, terpinen-4-ol, and beta-ocimene. Each soft gelatin capsule contains exactly 80mg of this standardized oil. Standardization is what makes it medicine: the clinical trials tested a specific, reproducible formulation, not a variably concentrated botanical.
The brand-name product Lasea is marketed in Germany, Austria, and parts of Europe. In the United States, Silexan is not FDA-approved as a drug and is sold as an over-the-counter dietary supplement. The critical difference between a legitimate Silexan product and a generic lavender capsule is the standardization to linalool and linalyl acetate content at defined percentages. Products that do not specify linalool concentration cannot be assumed to deliver the dose used in clinical trials.
Inhaled lavender aromatherapy has a small, inconsistent evidence base with methodological limitations, mostly around blinding and outcome measurement. The Silexan oral trials are in an entirely different evidentiary category: double-blind, randomized, placebo-controlled, with validated psychiatric assessment scales and active comparators including lorazepam and paroxetine.
The Lorazepam Comparison Trial (Woelk 2010)
The pivotal Silexan trial was published by Woelk and Schläfke in Phytomedicine (2010). The design enrolled 221 patients with mixed anxiety disorder (ICD-10: F41.1, F41.2, F41.3) and randomized them to either Silexan 80mg daily or lorazepam 0.5mg daily for six weeks in a double-blind format. The primary outcome was change in the Hamilton Anxiety Scale (HAMA) total score.
Results at six weeks: Silexan reduced mean HAMA score by 11.3 points (from 25.3 to 14.0). Lorazepam reduced mean HAMA score by 11.6 points (from 24.4 to 12.8). The difference was not statistically significant (p = 0.83). Both groups showed equivalent responder rates (HAMA reduction of 50% or more): Silexan 52.5%, lorazepam 54.2%. By the pre-specified non-inferiority margin, Silexan was non-inferior to lorazepam.
The safety profile diverged completely. Lorazepam patients reported sedation, coordination impairment, and cognitive slowing. Silexan patients reported primarily GI symptoms (burping due to the oil capsule), with no reports of sedation, no impaired psychomotor performance on standardized tests, and no withdrawal symptoms on discontinuation. The Physician’s Global Assessment rated both groups as equivalently improved, while the patient-reported quality of life scores favored Silexan on the dimension of cognitive clarity.
The GAD Trials: Kasper 2014 and 2015
Following the Woelk result, Kasper and colleagues conducted a larger placebo-controlled trial specifically in Generalized Anxiety Disorder (GAD, DSM-IV), the chronic anxiety disorder for which SSRIs are now first-line treatment. Published in the International Journal of Neuropsychopharmacology (2014), the trial enrolled 318 patients and randomized them to Silexan 80mg, Silexan 160mg, or placebo for ten weeks.
Both active doses significantly outperformed placebo. The 80mg group showed a mean HAMA reduction of 12.8 points versus 9.5 points in placebo (p < 0.01). Effect size (Cohen’s d) of 0.52 placed Silexan in the moderate-to-large range for an anxiolytic, comparable to published effect sizes for SSRIs in GAD (typically 0.4 to 0.6). The 160mg dose produced a slightly larger reduction but more GI side effects, establishing 80mg as the optimal dose.
The 2015 trial (Kasper, also in International Journal of Neuropsychopharmacology) directly compared Silexan 80mg to paroxetine 20mg (Paxil) in GAD over ten weeks in 539 patients. Silexan was non-inferior to paroxetine on HAMA reduction (mean reduction: 13.5 vs 14.1 points, p = 0.48). Adverse event rates told a different story: paroxetine 46.8%, Silexan 28.2%. The paroxetine group had significantly more sexual side effects, weight change, and discontinuation syndrome reports. No Silexan patient was reported to have discontinuation symptoms.
How Silexan Works: Voltage-Gated Calcium Channels, Not GABA
The mechanism of Silexan is one of the most clinically important aspects of the evidence, because it explains why the drug produces anxiolysis without dependence. Benzodiazepines work by enhancing GABA-A receptor activity, the brain’s primary inhibitory system. Enhanced GABAergic inhibition produces anxiety reduction but also sedation, muscle relaxation, amnesia, and, with chronic use, receptor downregulation leading to tolerance, dependence, and potentially severe withdrawal.
Silexan does not interact with GABA receptors. Its primary mechanism involves the inhibition of voltage-gated calcium channels (VGCCs) at presynaptic nerve terminals. Linalool and linalyl acetate, the two major active components, bind to and inhibit VGCCs, reducing calcium influx during neuronal depolarization. Less calcium means less neurotransmitter release from presynaptic terminals, producing a general reduction in excitatory neurotransmission throughout limbic circuits implicated in anxiety.
This mechanism has been confirmed in vitro using rat hippocampal neurons and in mammalian cell lines expressing specific VGCC subtypes. A 2012 study in Neurochemistry International demonstrated that linalool inhibited N-type and L-type VGCCs at concentrations achievable with oral 80mg dosing in humans. A second mechanism, 5-HT1A receptor partial agonism by linalool, has been confirmed in binding studies; 5-HT1A partial agonism is the mechanism of buspirone, an approved non-benzodiazepine anxiolytic.
Because VGCCs do not develop the same receptor downregulation profile as GABA-A receptors under chronic exposure, and because Silexan’s action is modulatory rather than amplificatory, the conditions for tolerance and physical dependence do not arise under normal dosing.
Why No Dependency or Tolerance Develops
Physical dependence on benzodiazepines develops through GABA-A receptor downregulation and reduced receptor sensitivity. The brain compensates for enhanced inhibition by reducing the number and sensitivity of GABA-A receptors. When the drug is removed, the compensated, low-GABA system produces net excitation, manifesting as rebound anxiety, insomnia, tremor, and in severe cases, seizures.
Silexan’s VGCC inhibition mechanism does not trigger the same compensatory cascade. VGCC modulation produces a dampening effect on excitatory transmission rather than enhancement of inhibitory transmission, and VGCCs do not undergo clinically significant downregulation under chronic linalool exposure at 80mg doses. The 2015 Kasper trial followed patients for ten weeks with no increase in adverse events over time and no withdrawal phenomena upon cessation, providing clinical corroboration of the mechanistic prediction.
The absence of sedation deserves specific mention. VGCCs are not uniformly distributed across brain regions. Linalool’s inhibitory effect at concentrations achieved with oral dosing appears preferentially active in limbic and hypothalamic circuits relevant to anxiety rather than in brainstem circuits controlling arousal and motor coordination. This regional selectivity, which has not been fully mapped but is supported by behavioral animal model data, explains why anxiolytic doses do not produce the sedation that characterizes benzodiazepine use.
Silexan vs SSRIs vs Benzodiazepines: Evidence Comparison
| Feature | Silexan 80mg | SSRI (e.g. paroxetine 20mg) | Benzodiazepine (e.g. lorazepam 0.5mg) |
|---|---|---|---|
| HAMA reduction (GAD trials) | 12.8-13.5 points | 14.1 points (Kasper 2015) | 11.6 points (Woelk 2010, mixed anxiety) |
| Mechanism | VGCC inhibition, 5-HT1A partial agonism | Serotonin reuptake inhibition | GABA-A positive allosteric modulation |
| Onset of effect | 2-4 weeks (similar to SSRI) | 2-6 weeks | 30-60 minutes (acute) |
| Physical dependence risk | None reported in trials | Discontinuation syndrome in ~20% of users | High; develops in 2-4 weeks of daily use |
| Cognitive impairment | None in trials | Mild in some users | Significant; impairs driving and memory |
| Sexual side effects | None reported | Common (20-40% of users) | Rare at low doses |
| Adverse event rate (trials) | 28.2% (mostly GI) | 46.8% (Kasper 2015) | Sedation, coordination impairment |
| FDA approval | No (dietary supplement in US) | Yes (GAD indication) | Yes (Schedule IV controlled substance) |
| Regulatory status (Europe) | Prescription medicine in Germany/Austria (Lasea) | Prescription medicine | Prescription medicine (controlled) |
The comparison to SSRIs is relevant because how SSRIs differ from SNRIs for anxiety directly affects treatment selection decisions. Silexan’s non-inferior efficacy profile and significantly lower adverse event rate make it a rational first-line consideration for mild to moderate GAD, particularly for patients who cannot tolerate SSRI sexual side effects or weight changes.
How to Find a Quality Product
The clinical trials used WS 1265, manufactured by Dr. Willmar Schwabe GmbH. In the US market, the branded Lasea product is not widely available through mainstream retail channels, but products sold as “Silexan” by supplement companies may contain the standardized extract if they specify linalool content of 36 to 38%.
When evaluating a product, check three things: (1) the label states “Lavandula angustifolia oil standardized to linalool,” (2) linalool content per capsule is specified at a minimum of 25-38%, and (3) the dose is 80mg per capsule. Products labeled only as “lavender extract” or “lavender essential oil capsule” without standardization data cannot be assumed to deliver a therapeutic dose.
Third-party testing (NSF, USP, ConsumerLab) is available for some Silexan products and provides independent verification of actual linalool content. Given the supplement market’s variable quality controls, third-party verified products represent a meaningful additional assurance for a compound where dose precision matters.
Patients managing anxiety alongside medication for other conditions should be aware that gabapentin, another medication sometimes prescribed off-label for anxiety, operates through a related but distinct calcium channel mechanism. The evidence on gabapentin dependency risk provides useful context for comparing non-benzodiazepine options for anxiety management.
For those weighing whether to pursue pharmacological treatment at all, pain reprocessing therapy and other mind-body approaches represent a parallel evidence track for anxiety-adjacent conditions where neurological sensitization plays a role.
Frequently Asked Questions
Does Silexan really work for anxiety, or is it just placebo?
Five randomized controlled trials with validated anxiety scales support Silexan’s efficacy. In the Woelk 2010 trial it matched lorazepam. In the Kasper 2014 trial it significantly outperformed placebo with a moderate-to-large effect size. In the Kasper 2015 trial it was non-inferior to paroxetine. Active comparator trials with non-inferior outcomes are the strongest evidence base available for an anxiolytic compound.
How does Silexan compare to Xanax or lorazepam?
In the direct comparison trial (Woelk 2010), Silexan 80mg and lorazepam 0.5mg produced statistically equivalent anxiety reduction over six weeks. The critical difference is safety: lorazepam carries dependence risk, cognitive impairment, and withdrawal risk with daily use. Silexan produced none of those effects in any published trial. For chronic daily anxiety treatment, Silexan’s risk profile is substantially more favorable.
Is lavender supplement safe for daily anxiety treatment?
In all published trials including ten-week durations, Silexan 80mg showed no serious adverse events. The most common side effect is GI discomfort and burping due to the oil capsule, reported in approximately 5 to 15% of users. No dependence, no withdrawal, no cognitive impairment, and no significant drug interactions have been documented in clinical trial populations through ten weeks of daily use.
How does Silexan compare to ashwagandha for anxiety?
Both have randomized controlled trial evidence for anxiety reduction, but Silexan’s trial quality is stronger. Silexan has been tested in head-to-head trials against approved pharmaceutical comparators (lorazepam, paroxetine) with non-inferior results. Ashwagandha trials typically use placebo controls only, with smaller samples and shorter follow-up. Silexan also has a better-characterized mechanism at the receptor level than ashwagandha.
How long does it take for Silexan to work?
Clinical trials show meaningful anxiety reduction within 2 to 4 weeks of daily 80mg dosing, a timeline similar to SSRIs. This contrasts with benzodiazepines, which act within 30 to 60 minutes but carry dependence risk with chronic daily use. Patients expecting immediate relief should understand that Silexan works through gradual neurochemical modulation, not acute sedation.